• Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups
  • Demonstrated substantial increases in daily "Good On" time, reductions in "Off" time, and meaningful improvements in motor function after switching to CREXONT®
  • Patients switching to CREXONT® from RYTARY® gained 3.07 hours of additional daily "Good On" time and nearly doubled the duration of continuous "Good On" intervals, enabling longer, uninterrupted periods of effective symptom control
     

BRIDGEWATER, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the 2026 American Academy of Neurology (AAN).

The first 111 patients evaluated after six weeks of treatment demonstrated substantial clinical benefit after switching to CREXONT® (carbidopa and levodopa) extended-release capsules, regardless of whether patients switched from immediate-release carbidopa/levodopa (IR CD/LD), IR CD/LD plus a COMT inhibitor, or RYTARY® (carbidopa and levodopa) extended-release capsules. These interim findings build on the established efficacy and safety profile of CREXONT demonstrated in the Phase 3 RISE-PD trial and reflected in the FDA-approved prescribing information.

After patients switched from prior therapies, treatment with CREXONT delivered meaningful increases in "Good On" time, reductions in "Off" time, and improved motor symptom control. Patients switching from RYTARY achieved consistent gains in continuous "Good On" intervals – the length of uninterrupted time patients spend feeling their best. The most common adverse events (≥3%) in the study were dizziness (9.0%), nausea (7.2%), falls (7.2%), dyskinesia (4.5%), hallucination (3.6%), and headache (3.6%).